Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-11

AUTHORS

Tarek A. Bismar, Samar Hegazy, Zhaoyong Feng, Darryl Yu, Bryan Donnelly, Nallasivam Palanisamy, Bruce J. Trock

ABSTRACT

OBJECTIVES: To assess the prognostic value of ERG and PTEN protein expression as two of the most common genetic aberration in men with prostate cancer managed non-surgically by androgen deprivation therapy (ADT). MATERIALS AND METHODS: 463 tumor samples were assessed by double immunohistochemistry stains for ERG and PTEN and data correlated with clinical pathological features including, Gleason score, patients' outcome and ADT. RESULTS: ERG expression and PTEN protein loss were present in 28.2% and 38% of total patients respectively. There was a significant interplay between ERG and PTEN expression with 21.8% PTEN negative tumors being ERG positive (p < 0.001). Both ERG and PTEN showed significant association with lethal disease in all patients and those treated with prior ADT representing castrate-resistant disease. However, only PTEN remained significant in multivariable proportional hazards regression analysis, when including Gleason score and patients' age. Depending on patient's subgroup, intact positive PTEN intensity showed better cancer-specific survival with HR ranging from 0.25 to 0.4 compared to tumors with loss of PTEN expression. Assessing combined marker status, patients with decreased PTEN intensity without ERG positivity showed the worst clinical outcome compared to those with no PTEN loss and no ERG expression, where they had best clinical outcome. Patients with ERG expression with or without PTEN loss showed intermediate risk in relation to lethal disease. CONCLUSION: This study confirms a significant prognostic role for assessing ERG and PTEN in men with prostate cancer. It supports a role for utilizing combined ERG/PTEN status clinically and prospectively for stratifying PCa patients into different prognostic groups. More... »

PAGES

2117-2125

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-018-2730-5

DOI

http://dx.doi.org/10.1007/s00432-018-2730-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106123802

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30101374


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Androgen Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "PTEN Phosphohydrolase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcriptional Regulator ERG", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Calgary Laboratory Services", 
          "id": "https://www.grid.ac/institutes/grid.418548.4", 
          "name": [
            "Department of Pathology and Laboratory Medicine, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada", 
            "Departments of Oncology, Biochemistry and Molecular Biology, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada", 
            "Arnie Charbonneau Cancer Institute, Tom Baker Cancer Center, Calgary, AB, Canada", 
            "Prostate Cancer Center, Calgary, AB, Canada", 
            "Rokyview General Hospital, Calgary Laboratory Services, 7007, 14th Street SW, T2V 1P9, Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bismar", 
        "givenName": "Tarek A.", 
        "id": "sg:person.01136762162.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136762162.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Calgary", 
          "id": "https://www.grid.ac/institutes/grid.22072.35", 
          "name": [
            "Department of Pathology and Laboratory Medicine, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hegazy", 
        "givenName": "Samar", 
        "id": "sg:person.01067444335.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067444335.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Johns Hopkins University", 
          "id": "https://www.grid.ac/institutes/grid.21107.35", 
          "name": [
            "Brady Urological Institute, John Hopkins School of Medicine, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feng", 
        "givenName": "Zhaoyong", 
        "id": "sg:person.011464324407.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011464324407.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Saskatchewan", 
          "id": "https://www.grid.ac/institutes/grid.25152.31", 
          "name": [
            "Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yu", 
        "givenName": "Darryl", 
        "id": "sg:person.01011415747.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011415747.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Calgary", 
          "id": "https://www.grid.ac/institutes/grid.22072.35", 
          "name": [
            "Department of Urology, University of Calgary, Calgary, AB, Canada", 
            "Prostate Cancer Center, Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donnelly", 
        "givenName": "Bryan", 
        "id": "sg:person.01241350724.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241350724.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Henry Ford Health System", 
          "id": "https://www.grid.ac/institutes/grid.239864.2", 
          "name": [
            "Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palanisamy", 
        "givenName": "Nallasivam", 
        "id": "sg:person.01316020452.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316020452.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Johns Hopkins University", 
          "id": "https://www.grid.ac/institutes/grid.21107.35", 
          "name": [
            "Brady Urological Institute, John Hopkins School of Medicine, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trock", 
        "givenName": "Bruce J.", 
        "id": "sg:person.01135165671.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135165671.58"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/pai.0000000000000119", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002930401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pai.0000000000000119", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002930401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.2014.85", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005769154", 
          "https://doi.org/10.1038/modpathol.2014.85"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-1049", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005947755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2010.09470.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010059072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2012.01.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011345133"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.291.22.2713", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019249000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.2008.96", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023686924", 
          "https://doi.org/10.1038/modpathol.2008.96"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12094-014-1182-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025674926", 
          "https://doi.org/10.1007/s12094-014-1182-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/jmg.35.9.790-a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030800406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.2011.176", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032668134", 
          "https://doi.org/10.1038/modpathol.2011.176"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-015-2096-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034546990", 
          "https://doi.org/10.1007/s00432-015-2096-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-015-2096-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034546990", 
          "https://doi.org/10.1007/s00432-015-2096-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5858/arpa.2011-0424-oa", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035039878"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.urology.2013.03.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037531675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.urolonc.2015.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040798893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1210237", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048310050", 
          "https://doi.org/10.1038/sj.onc.1210237"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605554", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048931941", 
          "https://doi.org/10.1038/sj.bjc.6605554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2016.09.084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048948178"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2016.09.084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048948178"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2016.09.084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048948178"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-1206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049831578"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1155/2013/786545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053327774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01621459.1999.10474144", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058305593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djv346", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059821600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.11.6.14376", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072292424"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.29689", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072293165"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074726014", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11", 
    "datePublishedReg": "2018-11-01", 
    "description": "OBJECTIVES: To assess the prognostic value of ERG and PTEN protein expression as two of the most common genetic aberration in men with prostate cancer managed non-surgically by androgen deprivation therapy (ADT).\nMATERIALS AND METHODS: 463 tumor samples were assessed by double immunohistochemistry stains for ERG and PTEN and data correlated with clinical pathological features including, Gleason score, patients' outcome and ADT.\nRESULTS: ERG expression and PTEN protein loss were present in 28.2% and 38% of total patients respectively. There was a significant interplay between ERG and PTEN expression with 21.8% PTEN negative tumors being ERG positive (p\u2009<\u20090.001). Both ERG and PTEN showed significant association with lethal disease in all patients and those treated with prior ADT representing castrate-resistant disease. However, only PTEN remained significant in multivariable proportional hazards regression analysis, when including Gleason score and patients' age. Depending on patient's subgroup, intact positive PTEN intensity showed better cancer-specific survival with HR ranging from 0.25 to 0.4 compared to tumors with loss of PTEN expression. Assessing combined marker status, patients with decreased PTEN intensity without ERG positivity showed the worst clinical outcome compared to those with no PTEN loss and no ERG expression, where they had best clinical outcome. Patients with ERG expression with or without PTEN loss showed intermediate risk in relation to lethal disease.\nCONCLUSION: This study confirms a significant prognostic role for assessing ERG and PTEN in men with prostate cancer. It supports a role for utilizing combined ERG/PTEN status clinically and prospectively for stratifying PCa patients into different prognostic groups.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00432-018-2730-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "144"
      }
    ], 
    "name": "Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification", 
    "pagination": "2117-2125", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3242ffd0579f3ccac984c69011b74e8f4b206719207fba72dc4c74b2d2a1bcea"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30101374"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7902060"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-018-2730-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106123802"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-018-2730-5", 
      "https://app.dimensions.ai/details/publication/pub.1106123802"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000605.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00432-018-2730-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2730-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2730-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2730-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2730-5'


 

This table displays all metadata directly associated to this object as RDF triples.

267 TRIPLES      21 PREDICATES      68 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-018-2730-5 schema:about N0c628ff70ced457d9f850e6d9e20e2f8
2 N1905d557e9bf4393b2e942dce9b91d38
3 N1db78ea418844d2da5c018098f608952
4 N2238ca81a186441a8c9f97a10a9bd154
5 N25aa382b8f5747a3b8c24a8e8dffc7cd
6 N44c2bd20c9bd4574a705a9c0638675c8
7 N5ee65254c79e4b2a877e208df67d8a1b
8 N699b15b783d3486aaa91229cb6dcf084
9 N8d218a96cc2c4c36b7e4e5e703d0fe0e
10 N938d6f7b9bab426aa304a8eb71baa53f
11 N9e3856e5cf0c498181c9a0f0e3225202
12 Na36ff3042b194f4a90c7d94ce7fbf141
13 Nb35ab924c0254998b155fdb91af40c5c
14 Nd2d670af2e654b95abe35501712de772
15 Ne8576ec91b0c4df9933ffd11a75a3121
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N46d55f8d70174be18e2f015d4f8faa63
19 schema:citation sg:pub.10.1007/s00432-015-2096-x
20 sg:pub.10.1007/s12094-014-1182-x
21 sg:pub.10.1038/modpathol.2008.96
22 sg:pub.10.1038/modpathol.2011.176
23 sg:pub.10.1038/modpathol.2014.85
24 sg:pub.10.1038/sj.bjc.6605554
25 sg:pub.10.1038/sj.onc.1210237
26 https://app.dimensions.ai/details/publication/pub.1074726014
27 https://doi.org/10.1001/jama.291.22.2713
28 https://doi.org/10.1016/j.ejca.2012.01.001
29 https://doi.org/10.1016/j.juro.2016.09.084
30 https://doi.org/10.1016/j.urology.2013.03.029
31 https://doi.org/10.1016/j.urolonc.2015.11.015
32 https://doi.org/10.1080/01621459.1999.10474144
33 https://doi.org/10.1093/jnci/djv346
34 https://doi.org/10.1097/pai.0000000000000119
35 https://doi.org/10.1111/j.1464-410x.2010.09470.x
36 https://doi.org/10.1136/jmg.35.9.790-a
37 https://doi.org/10.1155/2013/786545
38 https://doi.org/10.1158/1078-0432.ccr-12-1206
39 https://doi.org/10.1158/1078-0432.ccr-13-1049
40 https://doi.org/10.4161/cbt.11.6.14376
41 https://doi.org/10.4161/cbt.29689
42 https://doi.org/10.5858/arpa.2011-0424-oa
43 schema:datePublished 2018-11
44 schema:datePublishedReg 2018-11-01
45 schema:description OBJECTIVES: To assess the prognostic value of ERG and PTEN protein expression as two of the most common genetic aberration in men with prostate cancer managed non-surgically by androgen deprivation therapy (ADT). MATERIALS AND METHODS: 463 tumor samples were assessed by double immunohistochemistry stains for ERG and PTEN and data correlated with clinical pathological features including, Gleason score, patients' outcome and ADT. RESULTS: ERG expression and PTEN protein loss were present in 28.2% and 38% of total patients respectively. There was a significant interplay between ERG and PTEN expression with 21.8% PTEN negative tumors being ERG positive (p < 0.001). Both ERG and PTEN showed significant association with lethal disease in all patients and those treated with prior ADT representing castrate-resistant disease. However, only PTEN remained significant in multivariable proportional hazards regression analysis, when including Gleason score and patients' age. Depending on patient's subgroup, intact positive PTEN intensity showed better cancer-specific survival with HR ranging from 0.25 to 0.4 compared to tumors with loss of PTEN expression. Assessing combined marker status, patients with decreased PTEN intensity without ERG positivity showed the worst clinical outcome compared to those with no PTEN loss and no ERG expression, where they had best clinical outcome. Patients with ERG expression with or without PTEN loss showed intermediate risk in relation to lethal disease. CONCLUSION: This study confirms a significant prognostic role for assessing ERG and PTEN in men with prostate cancer. It supports a role for utilizing combined ERG/PTEN status clinically and prospectively for stratifying PCa patients into different prognostic groups.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree false
49 schema:isPartOf Nbaecfba98883420c884b61a851d63af3
50 Nbc0cd1d3bf7549018fa0dffd1d20c8b4
51 sg:journal.1313647
52 schema:name Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification
53 schema:pagination 2117-2125
54 schema:productId N0e2d4d7006e94511b8aaf26009df5212
55 N2955c065679f4a1d93f3712c6803a177
56 N4bfd01ea0e1a4436a4c1b634cf33721c
57 Nd678e07e1d9a44549c8b00d48f1ebad4
58 Nfb691895a81a46af8c245400cd17fde6
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106123802
60 https://doi.org/10.1007/s00432-018-2730-5
61 schema:sdDatePublished 2019-04-10T16:56
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N2d3d77b45139477cb520458a92d96815
64 schema:url https://link.springer.com/10.1007%2Fs00432-018-2730-5
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N0c628ff70ced457d9f850e6d9e20e2f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Prostatic Neoplasms
70 rdf:type schema:DefinedTerm
71 N0e2d4d7006e94511b8aaf26009df5212 schema:name doi
72 schema:value 10.1007/s00432-018-2730-5
73 rdf:type schema:PropertyValue
74 N1905d557e9bf4393b2e942dce9b91d38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Humans
76 rdf:type schema:DefinedTerm
77 N1db78ea418844d2da5c018098f608952 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Biomarkers, Tumor
79 rdf:type schema:DefinedTerm
80 N2238ca81a186441a8c9f97a10a9bd154 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Risk Assessment
82 rdf:type schema:DefinedTerm
83 N25aa382b8f5747a3b8c24a8e8dffc7cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Kaplan-Meier Estimate
85 rdf:type schema:DefinedTerm
86 N2955c065679f4a1d93f3712c6803a177 schema:name dimensions_id
87 schema:value pub.1106123802
88 rdf:type schema:PropertyValue
89 N2d3d77b45139477cb520458a92d96815 schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 N44c2bd20c9bd4574a705a9c0638675c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name PTEN Phosphohydrolase
93 rdf:type schema:DefinedTerm
94 N46d55f8d70174be18e2f015d4f8faa63 rdf:first sg:person.01136762162.11
95 rdf:rest N647bcf602c744ea7ae736e6a6320e8ca
96 N4bfd01ea0e1a4436a4c1b634cf33721c schema:name readcube_id
97 schema:value 3242ffd0579f3ccac984c69011b74e8f4b206719207fba72dc4c74b2d2a1bcea
98 rdf:type schema:PropertyValue
99 N549302e32d2346e1aad93bab57f0c881 rdf:first sg:person.01135165671.58
100 rdf:rest rdf:nil
101 N5ee65254c79e4b2a877e208df67d8a1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Aged, 80 and over
103 rdf:type schema:DefinedTerm
104 N647bcf602c744ea7ae736e6a6320e8ca rdf:first sg:person.01067444335.36
105 rdf:rest N7fa5ab352f764d11b4c074a3cf6019ff
106 N699b15b783d3486aaa91229cb6dcf084 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Immunohistochemistry
108 rdf:type schema:DefinedTerm
109 N6a45e087d27b4b5eb8740355c1b1a5a9 rdf:first sg:person.01316020452.03
110 rdf:rest N549302e32d2346e1aad93bab57f0c881
111 N7fa5ab352f764d11b4c074a3cf6019ff rdf:first sg:person.011464324407.26
112 rdf:rest Nc52325bb204e453eb7f15c317894c0bf
113 N80b066bf9e3044178b0279fcfca981ee rdf:first sg:person.01241350724.57
114 rdf:rest N6a45e087d27b4b5eb8740355c1b1a5a9
115 N8d218a96cc2c4c36b7e4e5e703d0fe0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Male
117 rdf:type schema:DefinedTerm
118 N938d6f7b9bab426aa304a8eb71baa53f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Transcriptional Regulator ERG
120 rdf:type schema:DefinedTerm
121 N9e3856e5cf0c498181c9a0f0e3225202 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Prognosis
123 rdf:type schema:DefinedTerm
124 Na36ff3042b194f4a90c7d94ce7fbf141 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Proportional Hazards Models
126 rdf:type schema:DefinedTerm
127 Nb35ab924c0254998b155fdb91af40c5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Aged
129 rdf:type schema:DefinedTerm
130 Nbaecfba98883420c884b61a851d63af3 schema:volumeNumber 144
131 rdf:type schema:PublicationVolume
132 Nbc0cd1d3bf7549018fa0dffd1d20c8b4 schema:issueNumber 11
133 rdf:type schema:PublicationIssue
134 Nc52325bb204e453eb7f15c317894c0bf rdf:first sg:person.01011415747.91
135 rdf:rest N80b066bf9e3044178b0279fcfca981ee
136 Nd2d670af2e654b95abe35501712de772 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Middle Aged
138 rdf:type schema:DefinedTerm
139 Nd678e07e1d9a44549c8b00d48f1ebad4 schema:name nlm_unique_id
140 schema:value 7902060
141 rdf:type schema:PropertyValue
142 Ne8576ec91b0c4df9933ffd11a75a3121 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Androgen Antagonists
144 rdf:type schema:DefinedTerm
145 Nfb691895a81a46af8c245400cd17fde6 schema:name pubmed_id
146 schema:value 30101374
147 rdf:type schema:PropertyValue
148 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
149 schema:name Medical and Health Sciences
150 rdf:type schema:DefinedTerm
151 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
152 schema:name Oncology and Carcinogenesis
153 rdf:type schema:DefinedTerm
154 sg:journal.1313647 schema:issn 0171-5216
155 1432-1335
156 schema:name Journal of Cancer Research and Clinical Oncology
157 rdf:type schema:Periodical
158 sg:person.01011415747.91 schema:affiliation https://www.grid.ac/institutes/grid.25152.31
159 schema:familyName Yu
160 schema:givenName Darryl
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011415747.91
162 rdf:type schema:Person
163 sg:person.01067444335.36 schema:affiliation https://www.grid.ac/institutes/grid.22072.35
164 schema:familyName Hegazy
165 schema:givenName Samar
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067444335.36
167 rdf:type schema:Person
168 sg:person.01135165671.58 schema:affiliation https://www.grid.ac/institutes/grid.21107.35
169 schema:familyName Trock
170 schema:givenName Bruce J.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135165671.58
172 rdf:type schema:Person
173 sg:person.01136762162.11 schema:affiliation https://www.grid.ac/institutes/grid.418548.4
174 schema:familyName Bismar
175 schema:givenName Tarek A.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136762162.11
177 rdf:type schema:Person
178 sg:person.011464324407.26 schema:affiliation https://www.grid.ac/institutes/grid.21107.35
179 schema:familyName Feng
180 schema:givenName Zhaoyong
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011464324407.26
182 rdf:type schema:Person
183 sg:person.01241350724.57 schema:affiliation https://www.grid.ac/institutes/grid.22072.35
184 schema:familyName Donnelly
185 schema:givenName Bryan
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241350724.57
187 rdf:type schema:Person
188 sg:person.01316020452.03 schema:affiliation https://www.grid.ac/institutes/grid.239864.2
189 schema:familyName Palanisamy
190 schema:givenName Nallasivam
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316020452.03
192 rdf:type schema:Person
193 sg:pub.10.1007/s00432-015-2096-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034546990
194 https://doi.org/10.1007/s00432-015-2096-x
195 rdf:type schema:CreativeWork
196 sg:pub.10.1007/s12094-014-1182-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1025674926
197 https://doi.org/10.1007/s12094-014-1182-x
198 rdf:type schema:CreativeWork
199 sg:pub.10.1038/modpathol.2008.96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023686924
200 https://doi.org/10.1038/modpathol.2008.96
201 rdf:type schema:CreativeWork
202 sg:pub.10.1038/modpathol.2011.176 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032668134
203 https://doi.org/10.1038/modpathol.2011.176
204 rdf:type schema:CreativeWork
205 sg:pub.10.1038/modpathol.2014.85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005769154
206 https://doi.org/10.1038/modpathol.2014.85
207 rdf:type schema:CreativeWork
208 sg:pub.10.1038/sj.bjc.6605554 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048931941
209 https://doi.org/10.1038/sj.bjc.6605554
210 rdf:type schema:CreativeWork
211 sg:pub.10.1038/sj.onc.1210237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048310050
212 https://doi.org/10.1038/sj.onc.1210237
213 rdf:type schema:CreativeWork
214 https://app.dimensions.ai/details/publication/pub.1074726014 schema:CreativeWork
215 https://doi.org/10.1001/jama.291.22.2713 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019249000
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1016/j.ejca.2012.01.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011345133
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1016/j.juro.2016.09.084 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048948178
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1016/j.urology.2013.03.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037531675
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/j.urolonc.2015.11.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040798893
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1080/01621459.1999.10474144 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058305593
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1093/jnci/djv346 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059821600
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1097/pai.0000000000000119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002930401
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1111/j.1464-410x.2010.09470.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010059072
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1136/jmg.35.9.790-a schema:sameAs https://app.dimensions.ai/details/publication/pub.1030800406
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1155/2013/786545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053327774
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1158/1078-0432.ccr-12-1206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049831578
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1158/1078-0432.ccr-13-1049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005947755
240 rdf:type schema:CreativeWork
241 https://doi.org/10.4161/cbt.11.6.14376 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072292424
242 rdf:type schema:CreativeWork
243 https://doi.org/10.4161/cbt.29689 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072293165
244 rdf:type schema:CreativeWork
245 https://doi.org/10.5858/arpa.2011-0424-oa schema:sameAs https://app.dimensions.ai/details/publication/pub.1035039878
246 rdf:type schema:CreativeWork
247 https://www.grid.ac/institutes/grid.21107.35 schema:alternateName Johns Hopkins University
248 schema:name Brady Urological Institute, John Hopkins School of Medicine, Baltimore, MD, USA
249 rdf:type schema:Organization
250 https://www.grid.ac/institutes/grid.22072.35 schema:alternateName University of Calgary
251 schema:name Department of Pathology and Laboratory Medicine, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada
252 Department of Urology, University of Calgary, Calgary, AB, Canada
253 Prostate Cancer Center, Calgary, AB, Canada
254 rdf:type schema:Organization
255 https://www.grid.ac/institutes/grid.239864.2 schema:alternateName Henry Ford Health System
256 schema:name Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.25152.31 schema:alternateName University of Saskatchewan
259 schema:name Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.418548.4 schema:alternateName Calgary Laboratory Services
262 schema:name Arnie Charbonneau Cancer Institute, Tom Baker Cancer Center, Calgary, AB, Canada
263 Department of Pathology and Laboratory Medicine, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada
264 Departments of Oncology, Biochemistry and Molecular Biology, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada
265 Prostate Cancer Center, Calgary, AB, Canada
266 Rokyview General Hospital, Calgary Laboratory Services, 7007, 14th Street SW, T2V 1P9, Calgary, AB, Canada
267 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...